abstract |
[0334] The present invention concerns improved methods and compositions for neoadjuvant nuse of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an nanthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin n(P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard antincancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. nNeoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer ntherapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred nembodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is nsuccessful in treating cancers that are resistant to standard treatments, such as triple-negative nbreast cancer (TNBC). |